Panobacumab clinical trials
How each study uses Panobacumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Panobacumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)CompletedPhase 3Aimmune Therapeutics, Inc.NCT03292484Written as AR101
- PALISADE Follow-on Study (ARC004)CompletedPhase 3Aimmune Therapeutics, Inc.NCT02993107Written as AR101
- Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OITCompletedPhase 2Aimmune Therapeutics, Inc.NCT01987817Written as AR101 powder provided in capsules
- Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On StudyCompletedPhase 2Aimmune Therapeutics, Inc.NCT02198664Written as AR101 - Peanut protein capsule
- Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)CompletedPhase 3Aimmune Therapeutics, Inc.NCT03126227Written as AR101
- AR101 Real-World Open-Label Extension StudyCompletedPhase 3Aimmune Therapeutics, Inc.NCT03337542Written as AR101
- Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas AeruginosaCompletedPhase 1/2Kenta Biotech LtdNCT00851435Written as KBPA-101
Given beside what is tested · 1 — Panobacumab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Panobacumab
Codes
What other systems call Panobacumab · ClinicalTrials.gg INT015174
- UNII (FDA) 62B4OXU259PANOBACUMABConfirmed FDA, Wikidata
- Wikidata Q7131437PanobacumabConfirmed FDA, Wikidata
- NCI Thesaurus C95791PanobacumabOne source FDA
- DrugBank DB15342One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 62B4OXU259 | PANOBACUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q7131437 | Panobacumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C95791 | Panobacumab | One source FDA |
| DrugBank | DB15342 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.